Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOTION-4
2024-518547-38-00Phase 4Authorised
- Sponsor
- Rigshospitalet
- Start
- Nov 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dabigatran, apixaban, clopidogrel, warfarin, aspirin and 2 more in aortic valve disease (AVD), aortic bioprosthetic valve degeneration (SVD) and thromboembolism (8 arms), sponsored by Rigshospitalet. Planned start Nov 2024; status: authorised.
02
Drugs
dabigatranapixabanclopidogrelwarfarinaspirin
03
Conditions
aortic valve disease (AVD)aortic bioprosthetic valve degeneration (SVD)thromboembolism
Beyond the preview
Go deeper on 2024-518547-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518547-38-00.